Exonic CLDN16 mutations associated with familial hypomagnesemia with hypercalciuria and nephrocalcinosis can induce deleterious mRNA alterations.


Journal

BMC medical genetics
ISSN: 1471-2350
Titre abrégé: BMC Med Genet
Pays: England
ID NLM: 100968552

Informations de publication

Date de publication:
08 01 2019
Historique:
received: 26 07 2018
accepted: 30 10 2018
entrez: 10 1 2019
pubmed: 10 1 2019
medline: 20 8 2019
Statut: epublish

Résumé

Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis type 1 is an autosomal recessive disease characterized by excessive renal magnesium and calcium excretion, bilateral nephrocalcinosis, and progressive chronic renal failure. This rare disease is caused by mutations in CLDN16 that encodes claudin-16, a tight-junction protein involved in paracellular reabsorption of magnesium and calcium in the renal tubule. Most of these variants are located in exons and have been classified as missense mutations. The functional consequences of some of these claudin-16 mutant proteins have been analysed after heterologous expression showing indeed a significant loss of function compared to the wild-type claudin-16. We hypothesize that a number of CLDN16 exonic mutations can be responsible for the disease phenotype by disrupting the pre-mRNA splicing process. We selected 12 previously described presumed CLDN16 missense mutations and analysed their potential effect on pre-mRNA splicing using a minigene assay. Our results indicate that five of these mutations induce significant splicing alterations. Mutations c.453G > T and c.446G > T seem to inactivate exonic splicing enhancers and promote the use of an internal cryptic acceptor splice site resulting in inclusion of a truncated exon 3 in the mature mRNA. Mutation c.571G > A affects an exonic splicing enhancer resulting in partial skipping of exon 3. Mutations c.593G > C and c.593G > A disturb the acceptor splice site of intron 3 and cause complete exon 4 skipping. To our knowledge, this is the first report of CLDN16 exonic mutations producing alterations in splicing. We suggest that in the absence of patients RNA samples, splicing functional assays with minigenes could be valuable for evaluating the effect of exonic CLDN16 mutations on pre-mRNA splicing.

Sections du résumé

BACKGROUND
Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis type 1 is an autosomal recessive disease characterized by excessive renal magnesium and calcium excretion, bilateral nephrocalcinosis, and progressive chronic renal failure. This rare disease is caused by mutations in CLDN16 that encodes claudin-16, a tight-junction protein involved in paracellular reabsorption of magnesium and calcium in the renal tubule. Most of these variants are located in exons and have been classified as missense mutations. The functional consequences of some of these claudin-16 mutant proteins have been analysed after heterologous expression showing indeed a significant loss of function compared to the wild-type claudin-16. We hypothesize that a number of CLDN16 exonic mutations can be responsible for the disease phenotype by disrupting the pre-mRNA splicing process.
METHODS
We selected 12 previously described presumed CLDN16 missense mutations and analysed their potential effect on pre-mRNA splicing using a minigene assay.
RESULTS
Our results indicate that five of these mutations induce significant splicing alterations. Mutations c.453G > T and c.446G > T seem to inactivate exonic splicing enhancers and promote the use of an internal cryptic acceptor splice site resulting in inclusion of a truncated exon 3 in the mature mRNA. Mutation c.571G > A affects an exonic splicing enhancer resulting in partial skipping of exon 3. Mutations c.593G > C and c.593G > A disturb the acceptor splice site of intron 3 and cause complete exon 4 skipping.
CONCLUSIONS
To our knowledge, this is the first report of CLDN16 exonic mutations producing alterations in splicing. We suggest that in the absence of patients RNA samples, splicing functional assays with minigenes could be valuable for evaluating the effect of exonic CLDN16 mutations on pre-mRNA splicing.

Identifiants

pubmed: 30621608
doi: 10.1186/s12881-018-0713-7
pii: 10.1186/s12881-018-0713-7
pmc: PMC6325764
doi:

Substances chimiques

Claudins 0
RNA Splice Sites 0
RNA, Messenger 0
claudin 16 0
Magnesium I38ZP9992A
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

6

Références

Genome Biol. 2010;11(2):R20
pubmed: 20158892
Gene. 2014 Aug 10;546(2):243-9
pubmed: 24907393
Genome Biol. 2014 Jan 13;15(1):R19
pubmed: 24451234
J Bone Miner Res. 2016 Mar;31(3):498-513
pubmed: 26426912
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11093-8
pubmed: 21685335
Nat Rev Genet. 2007 Oct;8(10):749-61
pubmed: 17726481
RNA. 2000 Sep;6(9):1197-211
pubmed: 10999598
Hum Mutat. 2008 Jul;29(7):975-82
pubmed: 18449911
PLoS Biol. 2004 Sep;2(9):E268
pubmed: 15340491
Kidney Int. 1995 May;47(5):1419-25
pubmed: 7637271
Am J Hum Genet. 2003 Dec;73(6):1293-301
pubmed: 14628289
Methods Mol Biol. 2000;132:365-86
pubmed: 10547847
Biosystems. 2018 Feb;164:39-48
pubmed: 29122587
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11193-8
pubmed: 11572975
PLoS Genet. 2016 Apr 06;12(4):e1005971
pubmed: 27049861
Kidney Int. 2001 Jun;59(6):2206-15
pubmed: 11380823
Mol Neurodegener. 2008 Jul 10;3:8
pubmed: 18616804
J Clin Invest. 2008 Feb;118(2):619-28
pubmed: 18188451
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W452-7
pubmed: 22689647
BMC Genomics. 2006 Sep 22;7:243
pubmed: 16995940
Pediatr Nephrol. 2003 Dec;18(12):1280-2
pubmed: 14586675
Hum Mutat. 2008 Dec;29(12):1412-24
pubmed: 18561205
J Cell Sci. 2005 Nov 1;118(Pt 21):5109-18
pubmed: 16234325
Hum Mutat. 2010 Jan;31(1):E1110-25
pubmed: 19953646
Methods Mol Biol. 2010;653:249-57
pubmed: 20721748
J Comput Biol. 1997 Fall;4(3):311-23
pubmed: 9278062
PLoS One. 2013;8(1):e53151
pubmed: 23301036
Science. 2015 Jan 9;347(6218):1254806
pubmed: 25525159
Nat Rev Genet. 2002 Apr;3(4):285-98
pubmed: 11967553
Hum Genet. 2017 Jun;136(6):665-677
pubmed: 28349240
Gene. 2016 Mar 1;578(1):117-23
pubmed: 26692149
Genome Biol. 2013 Dec 20;14(12):R143
pubmed: 24359918
Mol Genet Genomic Med. 2015 Jul;3(4):327-45
pubmed: 26247049
Clin Kidney J. 2015 Dec;8(6):656-64
pubmed: 26613020
Am J Hum Genet. 2006 Nov;79(5):949-57
pubmed: 17033971
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
RNA. 2008 May;14(5):802-13
pubmed: 18369186
Genes (Basel). 2018 Jan 04;9(1):
pubmed: 29300302
Curr Opin Nephrol Hypertens. 2007 Sep;16(5):459-64
pubmed: 17693762
Science. 2002 Aug 9;297(5583):1007-13
pubmed: 12114529
Mol Biol Evol. 2016 Feb;33(2):518-29
pubmed: 26545919
Physiol Rev. 2013 Apr;93(2):525-69
pubmed: 23589827
Nucleic Acids Res. 2009 May;37(9):e67
pubmed: 19339519
J Am Soc Nephrol. 2001 Sep;12(9):1872-81
pubmed: 11518780
Eur J Hum Genet. 2000 Jun;8(6):414-22
pubmed: 10878661
J Med Genet. 2017 Jan;54(1):26-37
pubmed: 27530400
Genome Biol. 2014 Jan 23;15(1):201
pubmed: 24456648
Adv Exp Med Biol. 2007;623:123-47
pubmed: 18380344
J Am Soc Nephrol. 2008 Jan;19(1):171-81
pubmed: 18003771
Science. 1999 Jul 2;285(5424):103-6
pubmed: 10390358
Clin J Am Soc Nephrol. 2012 May;7(5):801-9
pubmed: 22422540
Eur J Hum Genet. 2014 Dec;22(12):1362-8
pubmed: 24667779
Nat Rev Genet. 2016 Jan;17(1):19-32
pubmed: 26593421

Auteurs

Ana Perdomo-Ramirez (A)

Unidad de Investigación, Hospital Nuestra Señora de Candelaria, Carretera del Rosario 145, 38010, Santa Cruz de Tenerife, Spain.

Marian de Armas-Ortiz (M)

Unidad de Investigación, Hospital Nuestra Señora de Candelaria, Carretera del Rosario 145, 38010, Santa Cruz de Tenerife, Spain.

Elena Ramos-Trujillo (E)

Unidad de Investigación, Hospital Nuestra Señora de Candelaria, Carretera del Rosario 145, 38010, Santa Cruz de Tenerife, Spain.

Lorena Suarez-Artiles (L)

Unidad de Investigación, Hospital Nuestra Señora de Candelaria, Carretera del Rosario 145, 38010, Santa Cruz de Tenerife, Spain.

Felix Claverie-Martin (F)

Unidad de Investigación, Hospital Nuestra Señora de Candelaria, Carretera del Rosario 145, 38010, Santa Cruz de Tenerife, Spain. fclamar@gobiernodecanarias.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH